The addition of vaniprevir to pegylated interferon and ribavirin
significantly improved sustained virologic response among patients with
chronic hepatitis C in a recent study.
All treated groups experienced sustained virologic response (SVR) at 24
weeks more frequently than placebo patients (19% of cases; P<.001
for all comparisons). The highest SVR rate occurred in the group that
received 24 weeks of vaniprevir and 24 weeks of placebo (84.2% of
cases).Among patients who received 600 mg vaniprevir, 71.1% of
the 24-week group and 78% of the 48-week group achieved SVR, while 66.7%
experienced SVR in the 300-mg group.